Market Place
Sourcing Support
Mersana Therapeutics Reports Q3 2024 Results & Business Update
13 Nov 2024 //
GLOBENEWSWIRE
Mersana Therapeutics to Host Q3 2024 Call on Nov 13
06 Nov 2024 //
GLOBENEWSWIRE
Mersana Therapeutics Reports Q2 2024 Results And Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Mersana Therapeutics To Host Q2 2024 Call On August 13
06 Aug 2024 //
GLOBENEWSWIRE
Mersana Therapeutics to Present at Upcoming Investor Conferences
22 May 2024 //
GLOBENEWSWIRE
Mersana Q1 2024 Results And Business Update
09 May 2024 //
GLOBENEWSWIRE
Mersana Announces Nasdaq Listing Rule Inducement Grants
03 May 2024 //
GLOBENEWSWIRE
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
02 May 2024 //
GLOBENEWSWIRE
Mersana Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2024 //
GLOBENEWSWIRE
Mersana Announces Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
Mersana Therapeutics to Present at Upcoming Investor Conferences
27 Feb 2024 //
GLOBENEWSWIRE
Mersana to Host Fourth Quarter and Year End 2023 Conference Call
21 Feb 2024 //
GLOBENEWSWIRE
Mersana to Participate in Guggenheim™s 6th Annual Biotechnology Conference
01 Feb 2024 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Business Updates
05 Jan 2024 //
GLOBENEWSWIRE
It`s a wrap for Merck KGaA and Mersana`s 2014 ADC pact
23 Dec 2023 //
FIERCE BIOTECH
Mersana Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2023 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Mersana to Host Third Quarter 2023 Conference Call on November 7, 2023
31 Oct 2023 //
GLOBENEWSWIRE
Mersana`s phase 1 ADC cancer trial breaks free of FDA hold
31 Oct 2023 //
FIERCE BIOTECH
Mersana Therapeutics Announces Changes in Leadership
06 Sep 2023 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Mersana Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2023 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Topline Data from UPLIFT Trial in Patients
27 Jul 2023 //
GLOBENEWSWIRE
Mersana halves staff as shares plummet 75% in wake of trial fail
27 Jul 2023 //
FIERCE BIOTECH
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
06 Jul 2023 //
GLOBENEWSWIRE
Mersana Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Trials
15 Jun 2023 //
GLOBENEWSWIRE
Mersana Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jun 2023 //
GLOBENEWSWIRE
Mersana Therapeutics to Present at Upcoming Investor Conferences
24 May 2023 //
GLOBENEWSWIRE
Mersana Therapeutics Provides Business Update and Announces1Q 2023 FYR
09 May 2023 //
GLOBENEWSWIRE
Mersana Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 May 2023 //
GLOBENEWSWIRE
Mersana to Present at Bank of America Securities 2023 Healthcare Conference
03 May 2023 //
GLOBENEWSWIRE
Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023
02 May 2023 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO
26 Apr 2023 //
GLOBENEWSWIRE
Mersana Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Apr 2023 //
GLOBENEWSWIRE
U.S. FDA places Mersana`s cancer drug trial on hold following death
14 Mar 2023 //
REUTERS
Mersana Therapeutics Provides Statement About SVB
10 Mar 2023 //
GLOBENEWSWIRE
Mersana Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Mar 2023 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Fourth Quarter & Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call
21 Feb 2023 //
GLOBENEWSWIRE
Mersana Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Feb 2023 //
GLOBENEWSWIRE
Mersana Therapeutics to Present at Upcoming Investor Conferences
02 Feb 2023 //
GLOBENEWSWIRE
Mersana Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial
01 Feb 2023 //
GLOBENEWSWIRE
Mersana Announces Initiation of PI Trial of XMT-2056 in HER2-Expressing Tumors
25 Jan 2023 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing
06 Jan 2023 //
GLOBENEWSWIRE
Mersana Provides Business Update and Announces Strategic Objectives
06 Jan 2023 //
GLOBENEWSWIRE
Mersana signs deal with Merck KGaA for cancer therapy development
23 Dec 2022 //
REUTERS
European Commission Designates UpRi as an Orphan Medicinal Product
14 Dec 2022 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Inducement Grants Under Nasdaq
02 Dec 2022 //
GLOBENEWSWIRE
Mersana Therapeutics to Present at Jefferies London Healthcare Conference
08 Nov 2022 //
GLOBENEWSWIRE
Mersana Therapeutics Provides Business Update and Announces 3Q 2022 FY
07 Nov 2022 //
GLOBENEWSWIRE
Mersana Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Nov 2022 //
GLOBENEWSWIRE
Mersana Therapeutics to Host Third Quarter 2022 Conference on November 7, 2022
31 Oct 2022 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Completion of Enrollment in UPLIFT
06 Oct 2022 //
GLOBENEWSWIRE
Mersana Announces Launch of Oncology FACETS, a Resource for Healthcare
30 Sep 2022 //
GLOBENEWSWIRE
Mersana Announces FDA Fast Track Designation Granted to XMT-1660
13 Sep 2022 //
PRESS RELEASE
Mersana Therapeutics to Present at Upcoming Investor Conferences
06 Sep 2022 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
02 Sep 2022 //
GLOBENEWSWIRE
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-1660
16 Aug 2022 //
GLOBENEWSWIRE
GSK inks $1.3B biobucks deal for Mersana’s preclinical ADC
09 Aug 2022 //
FIERCEBIOTECH
Mersana Therapeutics Announces Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
